261 related articles for article (PubMed ID: 35577892)
1. Anti-nucleocapsid antibodies enhance the production of IL-6 induced by SARS-CoV-2 N protein.
Nakayama EE; Kubota-Koketsu R; Sasaki T; Suzuki K; Uno K; Shimizu J; Okamoto T; Matsumoto H; Matsuura H; Hashimoto S; Tanaka T; Harada H; Tomita M; Kaneko M; Yoshizaki K; Shioda T
Sci Rep; 2022 May; 12(1):8108. PubMed ID: 35577892
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 nucleocapsid protein, rather than spike protein, triggers a cytokine storm originating from lung epithelial cells in patients with COVID-19.
Wang YC; Tsai CH; Wang YC; Yen LC; Chang YW; Sun JR; Lin TY; Chiu CH; Chao YC; Chang FY
Infection; 2024 Jun; 52(3):955-983. PubMed ID: 38133713
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
4. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
[TBL] [Abstract][Full Text] [Related]
5. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ
Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 spike protein promotes IL-6 trans-signaling by activation of angiotensin II receptor signaling in epithelial cells.
Patra T; Meyer K; Geerling L; Isbell TS; Hoft DF; Brien J; Pinto AK; Ray RB; Ray R
PLoS Pathog; 2020 Dec; 16(12):e1009128. PubMed ID: 33284859
[TBL] [Abstract][Full Text] [Related]
7. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
[TBL] [Abstract][Full Text] [Related]
8. Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples.
Szymczak A; Jędruchniewicz N; Torelli A; Kaczmarzyk-Radka A; Coluccio R; Kłak M; Konieczny A; Ferenc S; Witkiewicz W; Montomoli E; Miernikiewicz P; Bąchor R; Dąbrowska K
J Gen Virol; 2021 Nov; 102(11):. PubMed ID: 34816794
[TBL] [Abstract][Full Text] [Related]
9. Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients.
Guo Y; Li T; Xia X; Su B; Li H; Feng Y; Han J; Wang X; Jia L; Bao Z; Li J; Liu Y; Li L
Front Immunol; 2021; 12():723585. PubMed ID: 34489974
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China.
Feng X; Yin J; Zhang J; Hu Y; Ouyang Y; Qiao S; Zhao H; Zhang T; Li X; Zhang L; Zhang J; Jin R; Feng Y; Su B
Front Immunol; 2021; 12():614436. PubMed ID: 33790892
[TBL] [Abstract][Full Text] [Related]
11. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
Front Immunol; 2020; 11():581338. PubMed ID: 33123167
[TBL] [Abstract][Full Text] [Related]
12. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
13. Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.
Schuler CF; Gherasim C; O'Shea K; Manthei DM; Chen J; Zettel C; Troost JP; Kennedy AA; Tai AW; Giacherio DA; Valdez R; Baldwin JL; Baker JR
Microbiol Spectr; 2021 Oct; 9(2):e0008721. PubMed ID: 34468184
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody therapy in COVID-19.
Conti P; Pregliasco FE; Calvisi V; Caraffa Al; Gallenga CE; Kritas SK; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(2):423-427. PubMed ID: 33904269
[TBL] [Abstract][Full Text] [Related]
15. S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit.
Nguyen-Contant P; Embong AK; Kanagaiah P; Chaves FA; Yang H; Branche AR; Topham DJ; Sangster MY
mBio; 2020 Sep; 11(5):. PubMed ID: 32978311
[TBL] [Abstract][Full Text] [Related]
16. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
[TBL] [Abstract][Full Text] [Related]
17. Tumor Necrosis Factor-Alpha Exacerbates Viral Entry in SARS-CoV2-Infected iPSC-Derived Cardiomyocytes.
Lee CY; Huang CH; Rastegari E; Rengganaten V; Liu PC; Tsai PH; Chin YF; Wu JR; Chiou SH; Teng YC; Lee CW; Liang Y; Chen AY; Hsu SC; Hung YJ; Sun JR; Chien CS; Chien Y
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576032
[TBL] [Abstract][Full Text] [Related]
18. N-terminally truncated nucleocapsid protein of SARS-CoV-2 as a better serological marker than whole nucleocapsid protein in evaluating the immunogenicity of inactivated SARS-CoV-2.
Yue L; Cao H; Xie T; Long R; Li H; Yang T; Yan M; Xie Z
J Med Virol; 2021 Mar; 93(3):1732-1738. PubMed ID: 32965677
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Induces Lymphocytopenia by Promoting Inflammation and Decimates Secondary Lymphoid Organs.
Xiang Q; Feng Z; Diao B; Tu C; Qiao Q; Yang H; Zhang Y; Wang G; Wang H; Wang C; Liu L; Wang C; Liu L; Chen R; Wu Y; Chen Y
Front Immunol; 2021; 12():661052. PubMed ID: 33995382
[TBL] [Abstract][Full Text] [Related]
20. Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients.
Varnaitė R; García M; Glans H; Maleki KT; Sandberg JT; Tynell J; Christ W; Lagerqvist N; Asgeirsson H; Ljunggren HG; Ahlén G; Frelin L; Sällberg M; Blom K; Klingström J; Gredmark-Russ S
J Immunol; 2020 Nov; 205(9):2437-2446. PubMed ID: 32878912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
